- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01881958
The Safety and Efficacy of Administrating DiaPep277® Vaccination in Type 1 Diabetes Patients.
Type 1 diabetes is caused by an autoimmune process resulting in a selective destruction of the pancreatic insulin-secreting beta-cell. DiaPep277® is a small, lyophilized powder containing 24 Amino-acids. We have proved in former studies that DiaPep277® can slow down beta cells destruction in the pancreas and therefore decelerate the progress of Diabetes.
The objective of the study is to assess the efficacy and safety of administrating DiaPep277® in type 1 diabetes patients.
Study Overview
Study Type
Phase
- Phase 2
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Fasting C-peptide levels >= 0.2nmol/L.
- Diagnosis of type 1 diabetes
- No pregnancies or planned pregnancies of female subjects
Exclusion Criteria:
- The subject has any significant diseases or conditions, including psychiatric disorders and substance abuse that, in the opinion of the Investigator, are likely to affect the subject's response to treatment or the ability to complete the study.
- The subject has a history of any kind of malignant tumor (not including basal cell skin cancer).
- The subject has clinical evidence of any diabetes-related complication that in the opinion of the Investigator would interfere with the subject's participation in and/or completion of the study.
Subject has history of endogenous allergic reactivity:
- Severe allergic reaction or severe exacerbation of allergic asthma within 12 months prior to the Screening-Ext Visit.
- Ongoing systemic asthma treatment.
- Subjects with history of life threatening or severe allergy, re-occurrence of which cannot be ruled out based on the Investigator's judgment.
- The subject has known allergy to lipid emulsions.
- The subject has a known immune deficiency from any disease, or a condition associated with an immune deficiency.
- The subject is receiving immunosuppressive or immunomodulating agents or cytotoxic therapy or any medication that in the opinion of the Investigator might interfere with the study.
The subject has any of the following clinically significant laboratory abnormalities:
- Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) greater than three times the upper limit of the normal (ULN) at the Screening-Ext Visit.
- Total bilirubin greater than 1.3 times the ULN at the Screening-Ext Visit.
- Subjects with severe renal failure at the Screening-Ext visit (as defined by glomerular filtration rate < 30 mL/min/1.73 m2 by Cockroft und Gault calculation • Clinically significant laboratory abnormalities, confirmed by repeat measurement, which may interfere with the assessment of safety and / or efficacy of the study drug, other than hyperglycemia and glycosuria at the Screening-Ext Visit.
- Fasting triglycerides <1000 mg/dL (11.3 mmol/L) at the Screening-Ext Visit. Suitable medical therapy for treatment of hyperlipidemia is allowed.
- The subject is a known or suspected drug abuser.
- The subject is known to test positive for HIV antibodies.
- The subject has chronic hematologic disease.
- The subject has liver disease such as cirrhosis or chronic active hepatitis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: DiaPep277®
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
efficacy will be measured by comparing Hemoglobin A1c
Time Frame: two years
|
two years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety will be evaluated calculating number of Adverse Events.
Time Frame: two years
|
two years
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 0224-13-HMO-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type One Diabetes
-
Washington University School of MedicineTerminatedType One Diabetes Mellitus
-
National Institute on Drug Abuse (NIDA)CompletedSee One | Do One | Order OneUnited States
-
Hadassah Medical OrganizationUnknownHypoglycemia | Type One DiabetesIsrael
-
King Faisal UniversityCompletedElective Video-assisted Thoracoscopic Surgery | One-lung Ventilation Lasts at Least One HourSaudi Arabia
-
University of EdinburghNHS LothianCompletedOne-Lung VentilationUnited Kingdom
-
Yonsei UniversityCompletedOne Lung VentilationKorea, Republic of
-
Radboud University Medical CenterCompleted
-
Sichuan UniversityWest China HospitalTemporarily not availableOne Lung Ventilation
-
Joseph D. TobiasCompletedOne-lung Ventilation (OLV)United States
-
Charite University, Berlin, GermanyCompletedDehiscent Type of Alveolar Bone Defect | One Stage Bone Augmentation
Clinical Trials on DiaPep277®
-
Andromeda Biotech Ltd.TerminatedType 1 DiabetesUnited States
-
Rabin Medical CenterTerminated
-
Andromeda Biotech Ltd.Completed
-
DeveloGen Israel, Ltd.Terminated
-
Andromeda Biotech Ltd.CompletedType 1 DiabetesFrance, Italy, United Kingdom, Israel, South Africa, Spain, Austria, Czech Republic, Finland, Germany, Greece
-
Andromeda Biotech Ltd.CompletedType 1 Diabetes MellitusUnited States, Russian Federation, Israel, Spain, Lithuania, Germany, Austria, Belarus, Canada, Czech Republic, Finland, Hungary, Italy, Poland
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China
-
Amir AzarpazhoohInstitut Straumann AGCompletedPeriodontal Inflammation | Crown LengtheningCanada